RT Journal Article SR Electronic T1 Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs JF bioRxiv FD Cold Spring Harbor Laboratory SP 2020.03.20.999730 DO 10.1101/2020.03.20.999730 A1 Sangeun Jeon A1 Meehyun Ko A1 Jihye Lee A1 Inhee Choi A1 Soo Young Byun A1 Soonju Park A1 David Shum A1 Seungtaek Kim YR 2020 UL http://biorxiv.org/content/early/2020/03/20/2020.03.20.999730.abstract AB COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of fifty FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 μM < IC50 < 10 μM) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide – were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.